Evaluation of the anti-C-C chemokine receptor type 4 monoclonal antibody mogamulizumab in patients with advanced cutaneous T-cell lymphomas and with large cell transformation

We aimed to compare the response to mogamulizumab in cutaneous T-cell lymphomas between patients with tumour status and/or large cell transformation and those without, and to investigate treatment effectiveness, depending on expression levels of C-C chemokine receptor type 4 (CCR4). We found that response to mogamulizumab at 8 weeks (primary endpoint) was significantly higher in patients without tumour status and/or large cell transformation. Conversely, no significant difference was found regarding CCR4 expression levels between mogamulizumab responders and nonresponders.